comparemela.com

Latest Breaking News On - Pinnacle associates - Page 8 : comparemela.com

Oder Investment Management LLC Has $566,000 Stake in Crocs, Inc (NASDAQ:CROX)

Oder Investment Management LLC decreased its position in Crocs, Inc. (NASDAQ:CROX – Free Report) by 2.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,056 shares of the textile maker’s stock after selling 167 shares during the period. Oder Investment Management LLC’s holdings in Crocs were […]

Beck Bode LLC Boosts Stake in Ferrari (NYSE:RACE)

Beck Bode LLC increased its position in shares of Ferrari (NYSE:RACE – Free Report) by 3.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,745 shares of the company’s stock after buying an additional 94 shares during the quarter. Beck Bode LLC’s holdings in […]

Certuity LLC Purchases 204 Shares of S&P Global Inc (NYSE:SPGI)

Certuity LLC lifted its stake in S&P Global Inc. (NYSE:SPGI – Free Report) by 18.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,306 shares of the business services provider’s stock after purchasing an additional 204 shares during the period. Certuity LLC’s holdings […]

GE HealthCare Technologies (NASDAQ:GEHC) Price Target Lowered to $86 00 at Bank of America

GE HealthCare Technologies (NASDAQ:GEHC) Price Target Lowered to $86 00 at Bank of America
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Q4 2025 Earnings Forecast for Esperion Therapeutics, Inc (NASDAQ:ESPR) Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.